Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative bioavailability of LY03004 vs EU Risperdal Consta 50 mg in schizophrenia
2016-005010-22Phase 3Completed
- Sponsor
- Luye Pharma Group
- Start
- May 2019
- Modality
- Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 3 trial of Risperdal Consta in schizophrenia, sponsored by Luye Pharma Group. Started May 2019; status: completed.
02
Drugs
Risperdal Consta
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2016-005010-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-005010-22.